Jeanette Acosta Invest in Women’s Health Act of 2026

317P–3. Demonstration project on co-testing for human papillomavirus and cervical cancer

(a) In general. The Secretary, in consultation with the Director of the Centers for Disease Control and Prevention and the Administrator of the Health Resources and Services Administration, as appropriate, shall establish a 2-year demonstration project on increasing the cervical cancer screening co-testing of human papillomavirus and cervical cytology (commonly referred to as Pap tests) to develop models for increasing the rates of co-testing among women with disproportionate rates of cervical cancer, including Black women; Hispanic and Latina women; and Asian American, Native Hawaiian, and Pacific Islander women.

(b) Use of funds. Entities receiving an award under this section shall use such award to—

(1) increase access to co-testing of human papillomavirus testing and cervical cancer among patients with disproportionate rates of cervical cytology, including Black women; Hispanic and Latina women; and Asian American, Native Hawaiian, and Pacific Islander women;

(2) support culturally and linguistically appropriate delivery models to such patients, including through the provision of interpretation services; or

(3) provide other services to improve health outcomes with respect to such patients.

(c) Prioritization. In making awards under this section, the Secretary shall give priority to eligible entities serving low-income, uninsured, or medically underserved populations (as defined in section 330(b)(3)) or populations with historically low rates of such co-testing, such as older women.

(d) Eligible entities. To be eligible to receive a grant under this section, an entity shall be an entity described in section 317P–2(c).